Larvol Delta - Primary-Resistance-to-Immune-Checkpoint-Inhibitor-Combination-Therapy-in-Metastatic-Renal-Cell-Carcinoma-Focus-on-Nivolumab-Plus-Ipilimumab

Yervoy (ipilimumab) - BMS

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

http://www.ncbi.nlm.nih.gov/pubmed/42717537

Kazuyuki Numakura; Noriyuki Abe

Sep 11, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next